Successful first year in the market for Marinomed’s Solv4U technology partnerships

EQS-News: Marinomed Biotech AG / Keyword(s): Conference

Successful first year in the market for Marinomed’s Solv4U technology partnerships
20.10.2022 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

Successful first year in the market for Marinomed’s Solv4U technology partnerships

  • Several feasibility studies carried out; the next stages of formulation and optimization must begin
  • Compounds of more than ten classes of substances successfully solubilized
  • Marinomed will be present at BioEurope in Leipzig, Germany from October 24 to 24, 2022 and CPHI in Frankfurt, Germany from November 01 to 03, 2022

Korneuburg, Austria, October 20, 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, today provided an update on the performance of Solv4U, a business line recently launched one year old. Solv4U offers Marinosolv Technology Partnerships to its customers, helping them develop formulations to increase both the solubility and bioavailability of hydrophobic small molecules and peptides at all stages of drug discovery and development. Partnerships typically begin with a feasibility study and then continue with formulation development and optimization.

In the first year following the launch of Solv4U, Marinomed has completed several feasibility studies, with the first projects now entering the formulation development phase. To date, compounds from more than ten substance classes have already been successfully solubilized using Marinosolv technology, including corticosteroids and other immunosuppressive drugs, phytochemicals, and substances intended for use in infectious diseases, oncology and central nervous system disorders.

“We are very pleased that in just one year after the launch of Solv4U, we have been able to further validate the exceptional potential of our Marinosolv technology by successfully solubilizing substances from a wide variety of chemical classes. The high success rate of our approach combined with the excellent safety and tolerability profile make Solv4U a respectable player in formulation development. We look forward to meeting future Solv4U partners at the next CPHI conference,” said dr. Andreas Grassauer, CEO of Marinomed.

Solv4U offers its customers access to Marinomed’s exclusive Marinosolv technology, patented in the main pharmaceutical markets of the world. Marinosolv’s saponin-based formulation is individually customized for each compound to dramatically improve solubility. It is suitable for a wide range of APIs. With its clinically validated Marinosolv lead product candidates, Tacrosolv and Budesolv, Marinomed has been able to demonstrate several key benefits: increased solubility leads to better permeation and bioavailability, more efficient drug delivery and significantly faster onset of action. Marinosolv also allows a significant reduction in the dose administered and therefore a reduced environmental footprint. Partners also benefit from an economic advantage: Marinosolv-based drugs are eligible for patent protection even if the active pharmaceutical ingredients (APIs) themselves are no longer protectable.

For more information about Solv4U, visit the new Solv4U website, contact Marinomed directly or meet us, in person or virtually, at BioEurope or CPHI:

ORGANIC Europe (link)
October 24-26, 2022 – Leipzig, Germany

The Marinomed BD team will be present in person and look forward to meeting you there. Meetings can be scheduled through the PartneringONE platform.

CPHI Worldwide® 2022 (link)
01-03 November 2022 – Messe Frankfurt, Frankfurt am, Germany and online

Company exhibit booth #91C76 is located in Hall 9.1 in the ICSE area.
In-person and virtual meetings with the Marinomed BD team can be scheduled through the conferencing platform or directly through [email protected]

Contact for Solv4U:
Susanne Bach, PhD, Senior Director BD&L
Marinomed Biotech AG, Hovengasse 25, 2100 Korneuburg, Austria
Email: [email protected]
Tel: +43 2262 90300

About Marinosol®:

Marinosolv® is an innovative technology platform that enables the solubilization and improves the bioavailability of small molecules and poorly soluble peptides in aqueous formulations. Consequently, new treatments for a multitude of diseases can be envisaged. The use of Marinosolv® The technology can facilitate the efficient delivery of drugs with low systemic off-target activity. Existing drugs and off-patent active ingredients can be improved and re-patented as part of new formulations using Marinosolv®. Under the Solv4U brand, Marinomed supplies Marinosolv® development of formulations in technology partnerships for active ingredients at all stages of drug discovery and for life cycle extension. For more information on Marinosolv® or Solv4U, please visit https://www.solv4u.com. Scientific publications on Marinosolv® can be accessed under the “Immunology” tabs at https://www.marinomed.com/en/news/scientific-publications.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian science-based biotechnology company with a growing development pipeline and globally marketed therapeutic products. The Company develops innovative products protected by patents in the therapeutic areas of immunology and virology based on the Marinosolv platform® and the virus blocking activity of iota-carrageenan. The Marinosolv® The technology improves the solubility and bioavailability of poorly soluble compounds and is used to develop new therapies for autoreactive immune disorders. The Virology segment includes over-the-counter products based on Carragelose® to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The company is headquartered in Korneuburg, Austria, and is listed on the main market of the Vienna Stock Exchange (VSE: MARI). For more information, please visit: https://www.marinomed.com.

For more information, contact:

Marinomed Biotech AG
PR: Lucia Mayr-Harting
T +43 2262 90300 158
Email: [email protected]
IR: Stephanie Kniep
T +43 2262 90300 226
Email: [email protected]
International media contact
MC Services SA
Dr Brigitte Keller, Dr Regina Lutz
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
Email: [email protected]

Disclaimer

This press release contains forward-looking statements based on the current opinions, expectations and projections of the management of Marinomed Biotech AG regarding future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, these statements. The current opinions, expectations and projections of the management of Marinomed Biotech AG can be identified by the context of such statements or words such as “anticipate”, “believe”, “estimate”, “expect”, “have the intention to”, “plan”, “project” and “target”. Forward-looking statements speak only as of the date they are made, and Marinomed Biotech AG undertakes no obligation to update, review or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and carrageenan® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in certain locations only.


20.10.2022 CET/CEST Broadcast of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

EQS distribution services include regulatory announcements, financial/corporate news and press releases.
Archives on www.eqs-news.com